SCHEMBL31371507
Butyrylcholinesterase inhibitor and poor p38alpha Mitogen-Activated Protein Kinase Inhibitor. IC50 hBChE 0.021 +/- 0.002 microM; residual activity at 100 microM AChE 51 +/- 3 %; residual activity at 100 microM p38alpha MAPK 93 +/- 25 %
General
Type : Multitarget, Carboxamide, Indazole, Piperidine, p38-MAPK-inhibitor
Chemical_Nomenclature : 2-(cyclohexylmethyl)-5-(2,4-difluorophenoxy)-N-[2-[3-(methoxymethyl)piperidin-1-yl]ethyl]indazole-6-carboxamide
Canonical SMILES : COCC1CCCN(C1)CCNC(=O)C2=CC3=NN(C=C3C=C2OC4=C(C=C(C=C4)F)F)CC5CCCCC5
InChI : InChI=1S\/C30H38F2N4O3\/c1-38-20-22-8-5-12-35(17-22)13-11-33-30(37)25-16-27-23(19-36(34-27)18-21-6-3-2-4-7-21)14-29(25)39-28-10-9-24(31)15-26(28)32\/h9-10,14-16,19,21-22H,2-8,11-13,17-18,20H2,1H3,(H,33,37)
InChIKey : OJJHRKPNNTZEQJ-UHFFFAOYSA-N
Other name(s) : 2-(Cyclohexylmethyl)-5-(2,4-difluorophenoxy)-N-(2-(3-(methoxymethyl)piperidin-1-yl)ethyl)-2H-indazole-6-carboxamide || Compound 102 || A1IZ3
MW : 540.6
Formula : C30H38F2N4O3
CAS_number :
PubChem : 176205036
UniChem : OJJHRKPNNTZEQJ-UHFFFAOYSA-N
Target
References (1)
| Title : Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38alpha Mitogen-Activated Protein Kinase Inhibitors - Ferjancic Benetik_2025_J.Med.Chem__ |
| Author(s) : Ferjancic Benetik S , Proj M , Knez D , Kosak U , Meden A , Krajsek K , Pislar A , Horvat S , Svajger U , Tesic N , Pulkrabkova L , Soukup O , Skarka A , Andrys R , Brazzolotto X , Igert A , Nachon F , Dias J , Detka J , Gdula-Argasinska J , Wyska E , Szafarz M , Manik A , Plachtij N , Musilek K , Salat K , Obreza A , Gobec S |
| Ref : Journal of Medicinal Chemistry , : , 2025 |
| Abstract : |
| PubMedSearch : Ferjancic Benetik_2025_J.Med.Chem__ |
| PubMedID: 40779804 |